Porphyromonas gingivalis fimbrial adhesin (FimA) (FimA)

Porphyromonas gingivalis adhesins are a diverse group of surface-exposed proteins, including fimbriae (FimA and Mfa1) and hemagglutinins (HagB), that are essential for the colonization and virulence of this keystone periodontal pathogen (UniProt P14602; Lamont & Jenkinson, 1998). These molecules facilitate the attachment of the bacteria to oral epithelial cells, the extracellular matrix, and other members of the oral biofilm through a process known as co-aggregation (Lin et al., 2006). The major fimbriae (FimA) specifically interact with host cell receptors like integrins and TLR2 to trigger signaling pathways that promote bacterial internalization and immune evasion (Hajishengallis et al., 2008). Beyond their role in chronic periodontitis, P. gingivalis adhesins are implicated in systemic diseases; for instance, they assist in the invasion of host cells and the subsequent release of gingipains, which have been linked to the pathogenesis of Alzheimer's disease and rheumatoid arthritis (Dominy et al., 2019; Potempa et al., 2017). Therapeutic targeting of these adhesins involves the development of subunit vaccines and small-molecule inhibitors designed to block bacterial adhesion and biofilm maturation (Zhang et al., 2005). Additionally, inhibitors of the gingipain complex, such as Atuzaginstat, indirectly affect adhesin function as these proteases often contain essential hemagglutinin/adhesin domains (Cortexyme, 2021). By preventing the initial stages of infection and colonization, these therapies aim to mitigate both local oral tissue destruction and the systemic inflammatory consequences associated with P. gingivalis infection (Olsen & Singhrao, 2015).

Other names

Major fimbriaeFimA proteinPorphyromonas gingivalis adhesinHemagglutinin B (HagB)Gingipain adhesin domainsMinor fimbriae (Mfa1)Hemagglutinin A (HagA)

Inhibition of bacterial attachment to host tissues and co-aggregation with other oral microbes, thereby preventing biofilm formation and subsequent tissue invasion; vaccine-mediated induction of neutralizing mucosal antibodies.